• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Innocare Gets Approval from NMPA for Orelabrutinib contractpharma
    January 08, 2021
    ​Innocare has received approval by the National Medical Products Administration of China (NMPA) for Orelabrutinib, an orally available potent BTK inhibitor that irreversibly binds to BTK to induce downstream kinase inactivation and cell death.
Previous page 1 2 3 4 5 6 7 Next page

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Event Data Sharing Notice
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service